

17 March 2025

**Physiomics plc**  
("Physiomics" or the "Company")

**Contract Award with new client**

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce a contract award with a new UK-based biotech company developing antibody drug conjugates (ADCs) based therapies targeting hard-to-treat cancers.

This new project will see the Company develop a Pharmacokinetic (PK) Pharmacodynamic (PD) model to inform optimal dosing for the client's upcoming First-in-Human trial. The project is valued at £102,000 and is projected to run from April 2025 until August 2025.

**Dr Peter Sargent, CEO, commented:**

*"We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments. This reflects the Company's strategy to diversify its client base, and expand its offering into new therapeutic modalities and areas of drug development."*

**Enquiries:**

**Physiomics plc**

Dr Peter Sargent, CEO

+44 (0)1235 841575

**Hybridan LLP (Broker)**

Claire Louise Noyce

+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**

James Dance & James Bellman

+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTFFFLLVSLIRLIE